Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Faron Pharmaceuticals Oy ( (GB:FARN) ) has provided an announcement.
Faron Pharmaceuticals Ltd announced the exercise of options by its CEO and CFO, resulting in the issuance of 111,000 new ordinary shares under the company’s 2015 Option Plan, generating gross proceeds of approximately EUR 120,990. This move is expected to impact the company’s equity structure, with the new shares set to be admitted to trading on Nasdaq First North Growth Market Finland and AIM, maintaining the total number of voting rights at 112,922,919.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel immunotherapies.
For detailed information about FARN stock, go to TipRanks’ Stock Analysis page.